Research Topics
Species | Richard R FurmanSummaryAffiliation: Cornell University Country: USA Publications
| Collaborators
|
Detail Information
Publications
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignanciesLuca Paoluzzi
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
Blood 112:2906-16. 2008..Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies...
CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemiaDianne Pulte
Research Service, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA
J Transl Med 5:23. 2007....
Epratuzumab in non-Hodgkin's lymphomasRichard R Furman
Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th Street, New York, NY 10021, USA
Curr Treat Options Oncol 5:283-8. 2004..Because of important differences in the characteristics of CD22 compared to CD20, epratuzumab may become an important component of future therapies for NHL...- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemiaRichard R Furman
Division of Hematology Oncology, Weill Cornell Medical College, New York, NY 10065, USA
Leuk Lymphoma 51:228-35. 2010..This modest single-agent activity may warrant further testing of dacetuzumab in combination with other chronic lymphocytic leukemia therapies... - Prognostic markers and stratification of chronic lymphocytic leukemiaRichard R Furman
Division of Hematology Oncology, Weill Cornell Medical College, New York, NY 10065, USA
Hematology Am Soc Hematol Educ Program 2010:77-81. 2010..While a great many prognostic markers have been identified that predict outcomes for patients with CLL. Learning how to use these prognostic markers to provide patient care is more difficult... - A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254Richard R Furman
Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY 10065, USA
Leuk Lymphoma 52:587-96. 2011..These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma... - Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom
Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY 10065, USA
Leuk Lymphoma 53:1469-73. 2012..Treatment was well tolerated with no unexpected toxicity. Although response rates did not meet predefined criteria, activity was at least comparable to other second-line approaches despite a poor-prognosis patient population... - Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaRichard R Furman
Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York 10021, USA
Cancer 116:5432-9. 2010..A phase 1 evaluation was conducted of bortezomib with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)... - Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones
Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 48:342-8. 2007..Two patients had objective responses of 1 and 42.4+ months, respectively. RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses... - Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan
Center for Lymphoma and Myeloma, Weill Cornell Medical College, 525 East 68th St, Starr 340, New York, NY 10065, USA
J Clin Oncol 29:690-7. 2011..We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)... - Outcome of deferred initial therapy in mantle-cell lymphomaPeter Martin
Starr Building Rm 340, Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
J Clin Oncol 27:1209-13. 2009..Because data on observation, or "watch and wait," have not been previously reported, we analyzed the outcome of deferred initial therapy... - Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphomaJia Ruan
Division of Hematology Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, New York, USA
Cancer 116:2655-64. 2010.... - Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik
Center for Lymphoma and Myeloma, Division of Hematology/Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
Cancer 106:616-22. 2006..CONCLUSIONS: Most patients with progressive disease after treatment with iodine I-131 tositumomab were able to receive subsequent therapy, including cytotoxic chemotherapy and stem cell transplantation... - Improving outcomes for patients with Burkitt lymphoma and HIVVictoria S Blinder
Divisions of Hematology Oncology and Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
AIDS Patient Care STDS 22:175-87. 2008..Further studies, including randomized clinical trials, are needed to better delineate the optimal treatment for patients with this devastating disease... - Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphomaPeter Martin
Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
Semin Hematol 45:126-32. 2008..Each of these strategies has shown varying degrees of preclinical and clinical success. In this review we discuss the rationale for various strategies and report results from clinical trials employing these agents... - Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz
Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Res 31:1141-4. 2007..Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting... - Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsisPeter Martin
Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
Clin Lymphoma Myeloma 9:247-9. 2009..An understanding of the pathophysiology of sepsis and immunologic activation that appear to have led to these long-term remissions might lead to novel therapeutic approaches for patients with HL... - Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
J Clin Oncol 23:5044-51. 2005..To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL)... - FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford
Centre for Lymphoma and Myeloma, Division of Haematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 49:719-26. 2008..Our findings support a potential role for preoperative FDG-PET in consideration of the need for splenectomy in these settings... - Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
J Clin Oncol 23:5696-704. 2005..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma... - Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphomaJohn P Leonard
Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, NY 10021, USA
Int J Cancer 119:971-9. 2006..A number of combination trials are currently underway with a range of standard agents. Bortezomib has the potential to play a significant role throughout the NHL treatment algorithm in the future... - Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphomaPeter Martin
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, New York 10021, USA
Clin Cancer Res 13:5636s-5642s. 2007..These promising therapeutics face a significant challenge in evaluation and integration in the post-rituximab world... - Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinibZibo Song
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA
Clin Cancer Res 16:587-99. 2010..We aim to define the molecular mechanisms underlying the differential dasatinib sensitivity and to uncover more effective therapeutic targets in CLL... - FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu
Department of Radiology, Division of Nuclear Medicine, Mount Sinai School of Medicine, New York, New York, USA
Cancer 107:2678-87. 2006.... - New developments in immunotherapy for non-Hodgkin's lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Curr Oncol Rep 7:364-71. 2005..Further studies of unlabeled and radiolabeled immunotherapies are ongoing in order to optimize their use for maximal clinical benefit... - Monoclonal antibodies in the treatment of non-Hodgkin's lymphomaRichard R Furman
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology and Weill Medical College of Cornell University and New York Presbyterian Hospital New York, NY, USA
Cancer Treat Res 131:221-50. 2006 - Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
J Clin Oncol 21:3051-9. 2003..This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin's lymphoma (NHL)... - Cutaneous CD4+ CD56+ hematologic malignanciesCynthia M Magro
Department of Pathology, Weill Medical College of Cornell University, New York, New York, USA
J Am Acad Dermatol 63:292-308. 2010..Hematologic malignancies expressing CD4 and CD56 are most commonly associated with the recently described CD4(+) CD56(+) hematodermic neoplasm... - Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40LMontserrat Cols
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
J Immunol 188:6071-83. 2012..These data indicate that BAFF, APRIL, and CD40L form a CLL-enhancing bidirectional signaling network linking neoplastic B cells with the microvascular stroma... - Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma cloneCory R Fraser
Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
Am J Clin Pathol 132:928-39. 2009..This phenomenon may be triggered by alterations in lineage-determining transcription programs, which result in transdifferentiation, coupled with additional oncogenic stimuli caused by chromosomal imbalances... - Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myelomaTomer Mark
Department of Medicine, Division of Hematology and Medical Oncology, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
Br J Haematol 143:654-60. 2008..This is the first time this phenomenon has been seen with regularity in non-myeloablative therapy for MM. Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response... - Persistent and relapsing babesiosis in immunocompromised patientsPeter J Krause
Division of Infectious Diseases, Connecticut Children s Medical Center, and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut 06106, USA
Clin Infect Dis 46:370-6. 2008..Although patients experiencing babesiosis that is unresponsive to standard antimicrobial therapy have been described, the pathogenesis, clinical course, and optimal treatment regimen of such cases remain uncertain...